Tactile Systems Technology, Inc. (NASDAQ:TCMD) VP Kristie Burns Sells 4,830 Shares

Tactile Systems Technology, Inc. (NASDAQ:TCMD) VP Kristie Burns sold 4,830 shares of the company’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $14.65, for a total value of $70,759.50. Following the transaction, the vice president now directly owns 84,008 shares of the company’s stock, valued at $1,230,717.20. This represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Tactile Systems Technology Stock Down 0.7 %

TCMD stock opened at $14.52 on Thursday. The company has a market cap of $342.45 million, a price-to-earnings ratio of 20.74 and a beta of 1.20. Tactile Systems Technology, Inc. has a twelve month low of $11.12 and a twelve month high of $21.10. The business has a 50 day moving average price of $17.09 and a two-hundred day moving average price of $15.72. The company has a quick ratio of 3.80, a current ratio of 4.36 and a debt-to-equity ratio of 0.11.

Tactile Systems Technology (NASDAQ:TCMD) last released its earnings results on Tuesday, February 18th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.09. The business had revenue of $85.59 million during the quarter, compared to analysts’ expectations of $85.39 million. Tactile Systems Technology had a net margin of 5.79% and a return on equity of 9.37%. Analysts anticipate that Tactile Systems Technology, Inc. will post 0.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TCMD shares. B. Riley downgraded Tactile Systems Technology from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $23.00 to $18.00 in a research report on Wednesday, February 19th. StockNews.com cut shares of Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 16th. BTIG Research downgraded shares of Tactile Systems Technology from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 5th. Finally, Oppenheimer cut shares of Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Tactile Systems Technology by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 1,483,692 shares of the company’s stock valued at $25,416,000 after purchasing an additional 4,509 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Tactile Systems Technology by 8.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 901,551 shares of the company’s stock valued at $15,444,000 after buying an additional 67,934 shares during the period. Wasatch Advisors LP raised its stake in Tactile Systems Technology by 9.8% in the third quarter. Wasatch Advisors LP now owns 727,194 shares of the company’s stock valued at $10,624,000 after buying an additional 64,684 shares during the period. Royce & Associates LP lifted its position in shares of Tactile Systems Technology by 2.5% in the third quarter. Royce & Associates LP now owns 612,979 shares of the company’s stock valued at $8,956,000 after buying an additional 14,780 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Tactile Systems Technology by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 558,667 shares of the company’s stock worth $8,164,000 after acquiring an additional 8,422 shares during the period. 83.43% of the stock is currently owned by institutional investors and hedge funds.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.